CytomX Therapeutics, Inc.
Clinical-stage oncology company developing conditionally activated biologics.
CTMX | US
Overview
Corporate Details
- ISIN(s):
- US23284F1057
- LEI:
- Country:
- United States of America
- Address:
- 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
- Website:
- https://cytomx.com/
- Sector:
- Manufacturing
Description
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CytomX Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
